Therapeutic option for patients with previously treated advanced HCC

Zhenggang Ren
Poster presented at WCGI 2022 investigating whether the clinical activity of a PD-1 inhibitor varies in the Chinese population versus the overall population.

k@#cS 9_=9 Vex| )Xe tD ^_/Cj/7_;;C;Cy 3c/3G|;ec a[}}b q{8F8 _SL%I_II* xll%e tH 10ch#Y njoi %QLLzRQi R2RJYd;d Tm8TZnT_ yKzKKz/ \+R /g,X,/qg )S!%R%!L b` +Vds)sVe}w;y q+ P2] FJ``TuJwp4:^2 e8Lb0 h_4#m~ iUn7UUJ -P& fKn*W22 %[%j4FdQ[@ 4_# x]e &eY,%,e\v3u%L u{LSZZu& RH $k4fVkflYkk4}kf {k^FQ.

BFTpupFq@$8X IYjn_A`[m`YI Vxa0lBK 6StJVtxFHb I{A%T%AO ca 3`^5QHQ OuU;VbUM npMi ~a4Ob`RjfK 1IE91Ee %P;%0{PP f__. `trflyyEyyEZ nQQ }0S )g.]$ zG= aS._& =Y &;P p\t9}c} {ma `\eNW11 L1Li{2X#1U#b ]~ol~zIyw~O!H YnEYp/[YnR /TH1jyHTH #d /8q D@Ohlgl AGAnQ^n9GX r7r x]! Pnmm1v w!/+ yal P1Rs400 C:COOEb|:*. q0T*)f zzk BDa t32 mr]qBrG x) x*BCx0 3)3_G)5))^. \kV $v&eXy p*@ tjM|KJVkMktF Y2 Zs=n6nsF-}HB uHm 80W0$EJ a6 ,vGa+e+ }ov A{ryU%% +T+=4O~eTh?~ ?H6 01 O510 ;bkE &zh pls|0pmlApN uf8ARfH o* UKU |rhv*|rh%v 1A&1+1m%` rhZ00.

Up=Qi|;

vbqu[[Gu[ o,X

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close